KEGG   DRUG: Ublituximab
Entry
D11243                      Drug                                   
Name
Ublituximab (USAN/INN);
Briumvi (TN)
Product
Formula
C6418H9866N1702O2006S48
Exact mass
144412.8918
Mol weight
144502.3284
Sequence
(Heavy chain)
QAYLQQSGAE LVRPGASVKM SCKASGYTFT SYNMHWVKQT PRQGLEWIGG IYPGNGDTSY
NQKFKGKATL TVGKSSSTAY MQLSSLTSED SAVYFCARYD YNYAMDYWGQ GTSVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
QIVLSQSPAI LSASPGEKVT MTCRASSSVS YMHWYQQKPG SSPKPWIYAT SNLASGVPAR
FSGSGSGTSY SFTISRVEAE DAATYYCQQW TFNPPTFGGG TRLEIKRTVA APSVFIFPPS
DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
(Disulfide bridge: H22-H96, H145-H201, H221-L213, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'213, H'262-H'322, H'368-H'426, L23-L87, L133-L193, L'23-L'87, L'133-L'193)
  Type
Peptide
Remark
ATC code: L04AG14
Product: D11243<US>
Efficacy
Antineoplastic, Anti-CD20 antibody
  Disease
Multiple sclerosis [DS:H01490]
  Type
Monoclonal antibody
Comment
Treatment of cancer, autoimmune disorders
Target
CD20 [HSA:931] [KO:K06466]
  Pathway
hsa04640  Hematopoietic cell lineage
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AG Monoclonal antibodies
     L04AG14 Ublituximab
      D11243  Ublituximab (USAN/INN) <US>
USP drug classification [BR:br08302]
 Central Nervous System Agents
  Multiple Sclerosis Agents
   Ublituximab
    D11243  Ublituximab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD20
     D11243  Ublituximab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11243
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11243
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11243
Other DBs
CAS: 1174014-05-1
PubChem: 384585221
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system